Alerte De Sécurité sur ARCHITECT Active-B12 Reagent Kit

Selon Department of Health, ce/cet/cette alerte de sécurité concerne un dispositif en/au/aux/à Hong Kong qui a été fabriqué par Abbott.

Qu'est-ce que c'est?

Les alertes fournissent des informations importantes et des recommandations concernant les dispositifs médicaux. Le fait qu'une alerte soit émise ne signifie pas nécessairement qu'un dispositif soit dangereux. Les alertes de sécurité, qui sont envoyées tant aux travailleurs du secteur médical qu'aux utilisateurs de ces dispositifs, peuvent inclure des rappels. Elles peuvent être rédigées par des fabricants mais aussi par des autorités en charge de la santé.

En savoir plus sur les données ici
  • Type d'événement
    Safety alert
  • Date
  • Date de publication de l'événement
  • Pays de l'événement
  • Source de l'événement
  • URL de la source de l'événement
  • Notes / Alertes
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notes supplémentaires dans les données
    Medical Device Safety Alert
  • Cause
    Medical device safety alert: abbott architect active-b12 reagent kit medical device manufacturer, abbott, has issued a medical device safety alert concerning its architect active-b12 reagent kit. the affected devices are identified as follows:- list number: (i) 3p24-25, (ii) 3p24-35 lot number: (i)10533up00, (ii)10534up00 udi number: (i) [(01) 00380740006365, (17) 170529, (10) 10533up00, (240) 3p2425] (ii) [(01) 00380740006372, (17) 170529, (10) 10534up00, (240) 3p2435] expiration date: 29 may 2017 the manufacturer has identified a lot specific stability issue with both reagent lots 10533up00 and 10534up00. as the reagent ages, relative light unit (rlu) values for the calibration curve will decrease causing patient results calculated from this depressed curve to over-recover, potentially resulting in falsely elevated patient results. controls may not reflect reagent instability as recalibration may result in control values within acceptable ranges. there is a potential for falsely elevated active-b12 results to be generated when using architect active-b12 reagent lots 10533up00 and 10534up00. internal studies have determined the worst case magnitude of elevation to be up to 30% for active-b12 concentrations close to 20 pmol/l and up to 20% for concentrations close to 30 pmol/l. affected users are instructed to discontinue use and immediately destroy any remaining inventory of architect active-b12 reagent lots 10533up00 and 10534up00 and order replacement material. they should also review the information with their medical director to determine if a review of results previously generated with reagent lots 10533up00 and 10534up00 is required. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 2 december 2016.


  • Modèle / numéro de série
  • Description du dispositif
    Medical Device Safety Alert: Abbott ARCHITECT Active-B12 Reagent Kit
  • Manufacturer


  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source